Zydus gets Mexico approval for diabetes drugs

Cadila Healthcare has said in a statement that the Mexican regulatory authority COFEPRIS has granted marketing approval to commercialise Lipaglyn (Saroglitazar magnesium) in Mexico. The drug is used to treat dyslipidemia in patients with diabetes mellitus type 2 and hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins. Zydus is also evaluating Saroglitazar to treat liver conditions.